Svebak S, Cameron A, Levander S
Department of Biological and Medical Psychology, University of Bergen, Norway.
J Clin Psychiatry. 1990 May;51 Suppl:14-7; discussion 50-3.
Data from 12 patients (in two control study groups) provide preliminary results of an ongoing double-blind comparison of clonazepam and imipramine in the treatment of panic disorder. In both treatment groups, the patients' global improvement was substantial over the first few weeks and persisted over the 6-month treatment period based on assessments by the therapist and the patient; side effects were mild. Faintness was slightly more prevalent among patients on clonazepam treatment but disappeared after the first few weeks. Mild, persistent tachycardia was reported among patients receiving imipramine. No tolerance emerged, and discontinuation was successful in 2 patients from each group after 6 months of treatment. Eight patients needed continued medication (25-50 mg/day of imipramine, 0.5-2.0 mg/day of clonazepam) to maintain substantial improvement. Findings confirm earlier reports from open studies that low doses of both drugs eliminate panic attacks (about 50 mg/day for imipramine and 1.5 mg/day for clonazepam).
来自12名患者（分属两个对照研究组）的数据提供了氯硝西泮和丙咪嗪治疗惊恐障碍正在进行的双盲比较的初步结果。在两个治疗组中，根据治疗师和患者的评估，患者在最初几周内整体改善显著，并在6个月的治疗期内持续；副作用轻微。服用氯硝西泮治疗的患者中头晕稍微更常见，但在最初几周后消失。接受丙咪嗪治疗的患者报告有轻度、持续性心动过速。未出现耐受性，每组各有2名患者在治疗6个月后成功停药。8名患者需要继续用药（丙咪嗪25 - 50毫克/天，氯硝西泮0.5 - 2.0毫克/天）以维持显著改善。研究结果证实了早期开放研究的报告，即两种药物的低剂量均可消除惊恐发作（丙咪嗪约50毫克/天，氯硝西泮1.5毫克/天）。
